An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor Defactinib VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Defactinib (Primary)
- Indications Mesothelioma
- Focus Biomarker; Pharmacodynamics
- Sponsors Verastem
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 10 May 2017 According to a Verastem media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting.
- 01 Feb 2017 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History